Abstract:Summary Background Macrophages at infection sites are considered as the promising therapeutic targets to prevent sepsis development. The Nrf2/Keap1 system acts as a critical modulator of the antibacterial activity of macrophages. Recently, Keap1–Nrf2 protein–protein interaction (PPI) inhibitors have emerged as safer and stronger Nrf2 activators; however, their therapeutic potential in sepsis remains unclear. Herein, we report a unique heptamethine dye, IR-61, as a Keap1–Nrf2 PPI inhibitor that preferentially accumulates in macrophages at infection sites. Methods A mouse model of acute lung bacterial infection was used to investigate the biodistribution of IR-61. SPR study and CESTA were used to detect the Keap1 binding behaviour of IR-61 in vitro and in cells. Established models of sepsis in mice were used to determine the therapeutic effect of IR-61. The relationship between Nrf2 levels and sepsis outcomes was preliminarily investigated using monocytes from human patients. Findings Our data showed that IR-61 preferentially accumulated in macrophages at infection sites, enhanced bacterial clearance, and improved outcomes in mice with sepsis. Mechanistic studies indicated that IR-61 potentiated the antibacterial function of macrophages by activating Nrf2 via direct inhibition of the Keap1–Nrf2 interaction. Moreover, we observed that IR-61 enhanced the phagocytic ability of human macrophages, and the expression levels of Nrf2 in monocytes might be associated with the outcomes of sepsis patients. Interpretations Our study demonstrates that the specific activation of Nrf2 in macrophages at infection sites is valuable for sepsis management. IR-61 may prove to be a Keap1-Nrf2 PPI inhibitor for the precise treatment of sepsis. Funding This work was supported by the National Natural Science Foundation of China (Major program 82192884 ), the Intramural Research Project (Grants: 2018-JCJQ-ZQ-001 and 20QNPY018 ), and the Chongqing National Science Foundation ( CSTB2022NSCQ-MSX1222 ).

Pathogen Infection-Responsive Nanoplatform Targeting Macrophage Endoplasmic Reticulum for Alleviating Sepsis

Pathogen infection-responsive nanoplatform targeting macrophage endoplasmic reticulum for treating life-threatening systemic infection

Nanoplatforms for Sepsis Management: Rapid Detection/Warning, Pathogen Elimination and Restoring Immune Homeostasis

Bioengineered Stem Cell Membrane Functionalized Nanoparticles Combine Anti-Inflammatory and Antimicrobial Properties for Sepsis Treatment

Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management.

Nanomaterials Targeting Macrophages in Sepsis: A Promising Approach for Sepsis Management

Antimicrobial peptide nanoparticles coated with macrophage cell membrane for targeted antimicrobial therapy of sepsis

An infection-microenvironment-targeted and responsive peptide-drug nanosystem for sepsis emergency by suppressing infection and inflammation

Inflammation-targeting Polymeric Nanoparticles Deliver Sparfloxacin and Tacrolimus for Combating Acute Lung Sepsis.

Precise engineering of neutrophil membrane coated with polymeric nanoparticles concurrently absorbing of proinflammatory cytokines and endotoxins for management of sepsis

Cascade-Targeted Nanoplatforms for Synergetic Antibiotic/ROS/NO/Immunotherapy against Intracellular Bacterial Infection

Macrophage biomimetic nanoparticle-targeted functional extracellular vesicle micro-RNAs revealed via multiomics analysis alleviate sepsis-induced acute lung injury

A Chemo/photo-responsive Immunomodulatory Nanoplatform for Treatment of Multidrug-Resistant Bacterial Sepsis

A small-molecule inhibitor of Keap1–Nrf2 interaction attenuates sepsis by selectively augmenting the antibacterial defence of macrophages at infection sites

Aggregated Carbon Dots‐loaded Macrophages Treat Sepsis by Eliminating Multidrug‐resistant Bacteria and Attenuating Inflammation

Ginsenoside Rb1-loaded Bionic Nanoparticles Alleviate Sepsis-Induced Acute Lung Injury by Reducing Mitochondrial Oxidative Stress to Inhibit Macrophage PANoptosis

Repolarization of Inflammation-Associated Macrophages by Dual Drug-Loaded Liposomes for Acute Lung Sepsis Antibacterial and Anti-inflammatory Therapy

Decoy Nanozymes Enable Multitarget Blockade of Proinflammatory Cascades for the Treatment of Multi-Drug-Resistant Bacterial Sepsis

Increased Susceptibility of S1PR3-Deficient Mice to Escherichia Coli Sepsis is Associated with an Impaired Bactericidal Activity in Macrophage

Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management

Vitamin Lipid Nanoparticles Enable Adoptive Macrophage Transfer for the Treatment of Multidrug-Resistant Bacterial Sepsis